E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers P > Headlines for PDL BioPharma, Inc. > News item
Published on 11/6/2008 in the Prospect News Special Situations Daily.

Iridian Asset Management reports stake of 10.8% in PDL BioPharma

By E. Janene Geiss

Philadelphia, Nov. 6 - Iridian Asset Management LLC reported an equity investment of 10.8% in PDL BioPharma, Inc. as of Oct. 31, according to an SC 13G filing with the Securities and Exchange Commission.

The passive stake represents 12,842,533 shares.

PDL BioPharma is a Wilmington, N.C., pharmaceutical company.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.